These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 17457808

  • 1. Safety update on the possible causal relationship between gadolinium-containing MRI agents and nephrogenic systemic fibrosis.
    Pedersen M.
    J Magn Reson Imaging; 2007 May; 25(5):881-3. PubMed ID: 17457808
    [No Abstract] [Full Text] [Related]

  • 2. On the potential causal relationship between gadolinium-containing MRI agents and nephrogenic systemic fibrosis.
    Partain CL.
    J Magn Reson Imaging; 2007 May; 25(5):879-80. PubMed ID: 17457806
    [No Abstract] [Full Text] [Related]

  • 3. Nephrogenic systemic fibrosis: an overview.
    Cowper SE.
    J Am Coll Radiol; 2008 Jan; 5(1):23-8. PubMed ID: 18180005
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Gadolinium and nephrogenic systemic fibrosis: association or causation.
    Kurtkoti J, Snow T, Hiremagalur B.
    Nephrology (Carlton); 2008 Jun; 13(3):235-41. PubMed ID: 18221255
    [Abstract] [Full Text] [Related]

  • 7. Nephrogenic systemic fibrosis: more questions and some answers.
    Morcos SK, Thomsen HS.
    Nephron Clin Pract; 2008 Jun; 110(1):c24-31; discussion c32. PubMed ID: 18688172
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinical and histological findings in nephrogenic systemic fibrosis.
    Cowper SE, Rabach M, Girardi M.
    Eur J Radiol; 2008 May; 66(2):191-9. PubMed ID: 18325705
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis.
    Shellock FG, Spinazzi A.
    AJR Am J Roentgenol; 2008 Oct; 191(4):1129-39. PubMed ID: 18806155
    [Abstract] [Full Text] [Related]

  • 13. Gadolinium-containing MRI contrast agents: important variations on a theme for NSF.
    Kuo PH.
    J Am Coll Radiol; 2008 Jan; 5(1):29-35. PubMed ID: 18180006
    [Abstract] [Full Text] [Related]

  • 14. Circulating fibrocytes: cellular basis for NSF.
    Bucala R.
    J Am Coll Radiol; 2008 Jan; 5(1):36-9. PubMed ID: 18180007
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Nephrogenic systemic fibrosis].
    Breitschaft A, Stahlmann R.
    Med Monatsschr Pharm; 2009 Oct; 32(10):377-82. PubMed ID: 19886227
    [Abstract] [Full Text] [Related]

  • 20. Nephrogenic systemic fibrosis: a serious iatrogenic disease of renal failure patients.
    Khurram M, Skov L, Rossen K, Thomsen HS, Marckmann P.
    Scand J Urol Nephrol; 2007 Oct; 41(6):565-6. PubMed ID: 17934986
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.